drugset
Drugs / VSV-ZEBOV
last change Nov 2019 re-read 3 minutes ago

VSV-ZEBOV

also known as BPSC1001 · rVSV-ZEBOV · rVSVΔG-ZEBOV-GP · V920

Vaccine

Developed for
Ebola hemorrhagic fever
Investigated by
Albert Schweitzer Hospital · Institute of Tropical Medicine, University of Tuebingen · Philipps University Marburg · University Hospital, Geneva · University Medical Center Hamburg-Eppendorf · Wellcome Trust
+3 more · World Health Organization · KEMRI-Wellcome Trust Collaborative Research Program · University of Oxford

Trials 2

today NCT02296983 · Ph 1 NCT02287480 · Ph 1/2
2015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 11 trial
Phase 1 NCT02296983 Dec 2014 → Feb 2016 Ebola hemorrhagic fever University of Oxford Unknown No outcome recorded
Phase 1/21 trial
Phase 1/2 NCT02287480 Nov 2014 → Apr 2015 Ebola hemorrhagic fever University Hospital, Geneva Completed No outcome recorded

Press releases naming this drug 2 releases

DateIssuerRelease
2019-11-11 Merck Sharp & Dohme LLC Merck’s ERVEBO® [Ebola Zaire Vaccine (rVSVΔG-ZEBOV-GP) live] Granted Conditional Approval in the European Union merck.com ↗
2019-10-18 Merck Sharp & Dohme LLC Merck Receives EU CHMP Positive Opinion for Investigational V920 Ebola Zaire Vaccine for Protection Against Ebola Virus Disease merck.com ↗

Evidence & citations 7 cited values

Every value below carries the sentence it was read from. 5 sources stand behind the page.

FieldValueCited text
Known as VSV-ZEBOV ClinicalTrials.gov intervention name — accepted as the source's own label NCT02296983 ↗
1

NCT02287480 ↗
Known as BPSC1001 “A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety and Immunogenicity of the BPSC1001 (VSVΔG-ZEBOV) Ebola Virus Vaccine Candidate in Healthy Adult Volunteers...” NCT02296983 ↗
Known as rVSV-ZEBOV “the recombinant vesicular stomatitis virus-based candidate vaccine expressing the Zaire Ebola virus glycoprotein (rVSV-ZEBOV; low-dose vaccinees)” PMID 26248510 ↗ Aug 2015
Known as rVSVΔG-ZEBOV-GP “The vaccine referred to as V920 is a recombinant vesicular stomatitis virus (rVSV) in which the VSV-G envelope glycoprotein (GP) is completely replaced by the Zaire ebolavirus...” PMID 28647166 ↗ Jun 2017
Known as V920 “The vaccine referred to as V920 is a recombinant vesicular stomatitis virus (rVSV) in which the VSV-G envelope glycoprotein (GP) is completely replaced by the Zaire ebolavirus...” PMID 28647166 ↗ Jun 2017
Modality Vaccine “The replication-competent recombinant vesicular stomatitis virus (rVSV)-based vaccine expressing a Zaire ebolavirus (ZEBOV) glycoprotein” PMID 25830326 ↗ Apr 2015
Route Intramuscular “One intramuscular (deltoid) injection” NCT02287480 ↗